Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

Research output: Contribution to journalReviewResearchpeer-review

  1. Biomarkers for early detection of kidney disease: a call for pathophysiological relevance

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup

    Research output: Contribution to journalReviewResearchpeer-review

  3. Adverse effects from selected antidotes commonly used in poisonings

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Baclofen toxicity results from intentional self-poisoning (acute baclofen poisoning) or accumulation of therapeutic dose in the setting of impaired kidney function. Standard care includes baclofen discontinuation, respiratory support and seizure treatment. Use of extracorporeal treatments (ECTRs) is controversial. To clarify this, a comprehensive review of the literature on the effect of ECTRs in baclofen toxicity was performed and recommendations following EXTRIP methods were formulated based on 43 studies (1 comparative cohort, 1 aggregate results cohort, 1 pharmacokinetic modeling, and 40 patient reports or series). Toxicokinetic data were available for 20 patients. Baclofen's dialyzability is limited by a high endogenous clearance and a short half-life in patients with normal kidney function. The workgroup assessed baclofen as "Moderately dialyzable" by intermittent hemodialysis for patients with normal kidney function (quality of evidence C) and "Dialyzable" for patients with impaired kidney function (quality of evidence C). Clinical data were available for 25 patients with acute baclofen poisoning and 46 patients with toxicity from therapeutic baclofen in kidney impairment. No deaths or sequelae were reported. Mortality in historical controls was rare. No benefit of ECTR was identified in patients with acute baclofen poisoning. Indirect evidence suggests a benefit of ECTR in reducing the duration of toxic encephalopathy from therapeutic baclofen in kidney impairment. These potential benefits were balanced against added costs and harms related to the insertion of a catheter, the procedure itself, and the potential of baclofen withdrawal. Thus, the EXTRIP workgroup suggests against performing ECTR in addition to standard care for acute baclofen poisoning and suggests performing ECTR in toxicity from therapeutic baclofen in kidney impairment, especially in the presence of coma requiring mechanical ventilation.

Original languageEnglish
JournalKidney International
Volume100
Issue number4
Pages (from-to)720-736
Number of pages17
ISSN0085-2538
DOIs
Publication statusPublished - Oct 2021

Bibliographical note

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Baclofen, Cohort Studies, Drug Overdose/therapy, Humans, Poisoning/therapy, Renal Dialysis, Seizures

ID: 68504569